NYSE:RCUSBiotechs
Assessing Arcus Biosciences (RCUS) Valuation After Trial Discontinuations Collaboration Setback And Weak Q1 Results
Arcus Biosciences (RCUS) has been in focus after first quarter 2026 results, which showed revenue of US$17 million and a net loss of US$128 million, alongside several pipeline and collaboration setbacks.
See our latest analysis for Arcus Biosciences.
The share price has been volatile around the recent Q1 2026 update and pipeline news. The 1 month share price return is 12.28% and the 90 day share price return is 17.83%, while the 1 year total shareholder return of 190.50% contrasts with a...